ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

Erin Jungmeyer
on: March 21, 2023In: Evolving Standards of Care, Industry News & Regulatory Approvals
Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients. Read more


Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

Erin Jungmeyer
on: March 07, 2023In: Evolving Standards of Care, Industry News & Regulatory Approvals, Uncategorized
Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint. Read more

CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says

Erin Jungmeyer
on: February 21, 2023In: Evolving Standards of Care
CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says

In a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC. Read more

Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?

Sophie M. Ernst, MD
+more
on: February 21, 2023In: Evolving Standards of Care
Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?

Study highlights limitations of relying solely on clinical smoking history, and findings suggest tobacco smoking-related mutational signatures could potentially guide molecular testing and optimize patient stratification in clinical trials. Read more

Increasing Evidence Demonstrates the Usefulness of ctDNA

Christian Rolfo, MD, PhD, MBA, Drhc
+more
on: February 07, 2023In: Evolving Standards of Care, Meeting News
Increasing Evidence Demonstrates the Usefulness of ctDNA

LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection. Read more

From the Editor: Looking Back on 2022

Corey Langer, MD
on: December 20, 2022In: Evolving Standards of Care
From the Editor: Looking Back on 2022

ILCN Editor Dr. Corey J. Langer reflects on highlights from the past year and looks at the year to come. Read more

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

Osa Ogbeide, MD
+more
on: December 06, 2022In: Evolving Standards of Care, Surgical Oncology
Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

In a “tale of two trials,” Drs. Ogbeide and Osarogiagbon use insights from the ALCHEMIST trial population to try to understand outcomes disparities between North America and Japan. Read more

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Erin Jungmeyer
on: November 22, 2022In: Evolving Standards of Care, Meeting News
Targeted Therapies Expanding for MET Dysregulation in NSCLC

During ACLC 2022, Dr. Noemi Reguart reviewed the data for MET-targeting TKIs and monoclonal antibodies for patients with METex14 skipping mutations, MET amplification, and MET overexpression. Read more

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Lei Deng, MD
+more
on: November 22, 2022In: Evolving Standards of Care
Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Beyond sotorasib, dozens of small molecule inhibitors are being explored to target this oncogenic driver. Get up to date as researchers from Roswell Park Comprehensive Cancer Center summarize the KRAS trial landscape. Read more

HER2 Mutations Present Unique Challenges in NSCLC

Stephanie P.L. Saw, MD
+more
on: November 08, 2022In: Evolving Standards of Care
HER2 Mutations Present Unique Challenges in NSCLC

Drs. Stephanie Saw and Daniel Tan stress the importance of understanding the intricacies of HER2 testing in non-small cell lung cancer to optimize patient selection. Read more

1234›»
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy